ABSTRACT
Imiquimod 5% cream (Aldara, Graceway Pharmaceuticals) is an immune response modifier used for the topical treatment of anogenital warts in non-HIV-infected patients. Several randomized controlled trials have demonstrated that imiquimod 5% cream is a safe and efficacious treatment. Current data regarding efficacy shows that complete clearance of warts occurred in up to 50% of patients treated with imiquimod 5% cream applied once-daily, 3 times per week for up to 16 weeks. Recurrence rates ranged from up to 19% at 3 months to 23% at 6 months. Imiquimod 5% cream showed an acceptable safety profile; local inflammatory reactions were the most frequent adverse effects, with local erythema being the most common.
Subject(s)
Aminoquinolines/therapeutic use , Condylomata Acuminata/drug therapy , Interferon Inducers/therapeutic use , Administration, Cutaneous , Aminoquinolines/administration & dosage , Aminoquinolines/adverse effects , Anus Diseases/drug therapy , Anus Diseases/surgery , Anus Diseases/virology , Combined Modality Therapy , Condylomata Acuminata/surgery , Condylomata Acuminata/virology , Female , Humans , Imiquimod , Interferon Inducers/administration & dosage , Interferon Inducers/adverse effects , Male , Secondary PreventionABSTRACT
Recurrent herpes labialis (RHL) is a common condition associated with the formation of vesicles around the mouth, often preceded by prodromal symptoms including tingling and burning. Treatment is targeted toward individual episodes, but in severe cases, suppressive therapy may be indicated. At present, no cure exists for this troublesome condition. The purpose of this article is to serve as a practical guide in the management of RHL by summarizing current treatments and discussing potential new therapies.
Subject(s)
Antiviral Agents/therapeutic use , Herpes Labialis/drug therapy , Administration, Cutaneous , Administration, Oral , Antiviral Agents/administration & dosage , Antiviral Agents/pharmacology , Drug Therapy, Combination , Herpes Labialis/virology , Humans , Recurrence , Severity of Illness IndexABSTRACT
Psoriasis is a common chronic inflammatory skin disease that is mediated, in part by the body's T-cell inflammatory response mechanisms. Further insight into the pathogenesis of the disease and the role of various cytokines, particularly interleukin(IL)-12 and IL-23, has led to advances in the treatment of this disease. A relatively new class of drugs that inhibit these interleukins is being developed and studied. Current data regarding the efficacy of these agents show they may have the potential to become the new clinical gold standard for biologic therapy to treat psoriasis.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Interleukin-12/antagonists & inhibitors , Interleukin-23/antagonists & inhibitors , Psoriasis/drug therapy , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal, Humanized , Humans , Psoriasis/immunology , UstekinumabABSTRACT
Atypical presentations of typical dermatological conditions are common in human immunodeficiency virus (HIV). This article will focus on three specific topics: eosinophilic folliculitis, psoriasis, and cutaneous mycoses. Their unique presentations in HIV and treatments are discussed.
Subject(s)
Dermatomycoses/physiopathology , Folliculitis/physiopathology , HIV Infections/complications , Psoriasis/physiopathology , Antifungal Agents/therapeutic use , Antiretroviral Therapy, Highly Active , Antiviral Agents/therapeutic use , Dermatomycoses/drug therapy , Dermatomycoses/etiology , Folliculitis/drug therapy , Folliculitis/etiology , HIV Infections/drug therapy , Humans , Psoriasis/drug therapy , Psoriasis/etiologyABSTRACT
A patient with homozygous sickle cell anemia is the youngest known to have died from acute splenic sequestration crisis. A cord blood screening program might have prevented this infant's death.
